RECRUITING

The Effect of Structured Lifestyle Modification and Yoga Practice on Metabolic Processes Associated With Cardiovascular Disease

Conditions

Coronary Artery Disease metabolic abnormality chair yoga micro RNA

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The aim of the prospective randomized single center study is to evaluate the effect of a short-term (16 weeks) yoga program on micro RNA (miRNA) expression and cardiovascular disease (CVD) risk factors in patients with CVD.

Official Title

The Effect of Structured Lifestyle Modification and Yoga Practice on Metabolic Processes Associated With Cardiovascular Disease

Quick Facts

Study Start:2022-01-24

Study Completion:2025-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05250310

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Subjects eligible for the study are 18-80 year old adults. * Underwent percutaneous coronary intervention (PCI) at the catheterization lab of Mount Sinai Hospital (New York, New York) or have non-obstructive coronary artery disease and at least one CVD risk factor (hypertension, hypercholesterolemia, diabetes mellitus, or obesity) or metabolic abnormality (fasting plasma glucose ≥ 100 mg/dl, documented previous diagnosis of hypertension, serum triglycerides ≥ 150 mg/dl, or HDL cholesterol \< 40 mg/dl). * Subjects diagnosed with metabolic syndrome, which is defined as three or more of the following conditions: (1) Central or abdominal obesity (waist circumference \> 40 inches for men and \> 35 inches for women); (2) High triglycerides (≥150 mg/dL or triglycerides treatment); (3) Low HDL cholesterol (\<40 mg/dL for men and \<50 mg/dL for women) or low HDL-C treatment; (4) High blood pressure (≥130/85 mmHg) or antihypertensive medications; (5) High fasting glucose (≥100 mg/dL) or type 2 diabetes mellitus. * Participants must be able to willingly consent to study participation and must be able to comply with the study requirements.	* Physical/psychological limitation or unwillingness to practice yoga, * Congestive heart failure, known arrthymias or prior Automated Implantable Cardioverter-Defibrillator /pacemaker or any metallic implants, * Rheumatological/immunological diseases, * History of transplant, * Moderate to severe chronic obstructive pulmonary disease, debilitating or severe systemic Illness, * Subjects who are pregnant or postpartum less than 6 months, * Liver disease or alcohol use of more than 7 alcoholic drinks/week in women and more than 14 drinks/week in men

Inclusion Criteria

Exclusion Criteria

* Subjects eligible for the study are 18-80 year old adults.
* Underwent percutaneous coronary intervention (PCI) at the catheterization lab of Mount Sinai Hospital (New York, New York) or have non-obstructive coronary artery disease and at least one CVD risk factor (hypertension, hypercholesterolemia, diabetes mellitus, or obesity) or metabolic abnormality (fasting plasma glucose ≥ 100 mg/dl, documented previous diagnosis of hypertension, serum triglycerides ≥ 150 mg/dl, or HDL cholesterol \< 40 mg/dl).
* Subjects diagnosed with metabolic syndrome, which is defined as three or more of the following conditions: (1) Central or abdominal obesity (waist circumference \> 40 inches for men and \> 35 inches for women); (2) High triglycerides (≥150 mg/dL or triglycerides treatment); (3) Low HDL cholesterol (\<40 mg/dL for men and \<50 mg/dL for women) or low HDL-C treatment; (4) High blood pressure (≥130/85 mmHg) or antihypertensive medications; (5) High fasting glucose (≥100 mg/dL) or type 2 diabetes mellitus.
* Participants must be able to willingly consent to study participation and must be able to comply with the study requirements.

* Physical/psychological limitation or unwillingness to practice yoga,
* Congestive heart failure, known arrthymias or prior Automated Implantable Cardioverter-Defibrillator /pacemaker or any metallic implants,
* Rheumatological/immunological diseases,
* History of transplant,
* Moderate to severe chronic obstructive pulmonary disease, debilitating or severe systemic Illness,
* Subjects who are pregnant or postpartum less than 6 months,
* Liver disease or alcohol use of more than 7 alcoholic drinks/week in women and more than 14 drinks/week in men

Contacts and Locations

Study Contact

Yuliya Vengrenyuk

CONTACT

212-241-0460

yuliya.vengrenyuk@mountsinai.org

Principal Investigator

Annapoorna Kini, MD

PRINCIPAL_INVESTIGATOR

MOUNT SINAI HOSPITAL

Study Locations (Sites)

Mount Sinai Hospital

New York, New York, 10029

United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

Annapoorna Kini, MD, PRINCIPAL_INVESTIGATOR, MOUNT SINAI HOSPITAL

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-01-24

Study Completion Date2025-12

Study Record Updates

Study Start Date2022-01-24

Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

Coronary artery disease
metabolic abnormality
chair yoga
micro RNA

Additional Relevant MeSH Terms

Coronary Artery Disease